Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : GENSET - GENXY -- Ignore unavailable to you. Want to Upgrade?

To: Mike McFarland who wrote (61)	4/13/2000 3:17:00 AM
From: nigel bates	Respond to of 200

Something to cheer you (& me) up Mike. PARIS, April 13 /PRNewswire/ -- Genset (Nasdaq: GENXY; Nouveau Marche: GENSET) today announced the signature of an agreement with Sanofi-Synthelabo to pursue a pharmacogenomics collaboration aimed at lead selection and optimization for an undisclosed CNS disease. Several pharmacogenetic studies have shown that genetic differences among individuals, or polymorphisms, in the molecular structure of given biological targets such as enzymes or receptors can cause variability in target lead interactions and result in variation in the activity of given lead compounds. The pharmacogenomics collaboration undertaken by Genset and Sanofi-Synthelabo has as its initial objective to comprehensively discover and analyze significant polymorphisms in a large number of different biological targets for drug development. Sanofi-Synthelabo is developing several compounds that interact with these targets. Genset will use its genomics and molecular biology technology platform to identify the most significant polymorphisms in the patient population and to generate corresponding clone variants. Sanofi-Synthelabo will use the polymorphism data and clones provided by Genset to perform further testing on the various leads it has in development and to optimize its lead selection process. As a result certain leads may be modified or replaced, while others will continue their development plan without any changes. Under the agreement, Sanofi-Synthelabo will provide research funding and research milestone fees to Genset and will pay clinical milestones and royalties on any drugs developed through an active use of the data and clones provided by Genset. Such active uses will notably include the chemical modification or the replacement of a given lead, or the use of data to design novel clinical studies. Genset will grant to Sanofi-Synthelabo an exclusive worldwide license to use the data and clones generated through the collaboration to develop and commercialize drugs for the treatment of the undisclosed selected disease. Said Pascal Brandys, Chairman & CEO: ``We are extremely pleased with Sanofi-Synthelabo's decision to include pharmacogenomics as a contribution to their ongoing selection process at various preclinical and clinical development stages of key molecules. Their lead selection process may significantly benefit from the incorporation, at early stages, of key information on target polymorphisms in patients. With this third major pharmacogenomics collaboration, we showcase once again that the high-throughput genotyping, epidemiological and biostatistical expertise we have assembled at Genset allows us to pioneer new applications to help optimize the development efforts of pharmaceutical companies.'